Jun 15, 2022 / 05:00PM GMT
Amit Hazan - Goldman Sachs Group, Inc., Research Division - Equity Analyst
All right. Good morning, everyone. Hope you can hear me okay. I'm Amit Hazan. I'm a medical technology analyst here at Goldman Sachs, and I'm getting ready to kick off Day 3 for the med-tech conversations at least. And we're really excited to have back with us at this conference, LivaNova, and we've got the whole crew here with us. First, before I introduce them, Phil Coover, one of my partners on the med-tech team is here too to ask questions.
And so we've got CEO, Damien McDonald; CFO Alex Shvartsburg; and Senior Vice President and Corporate Development Matt Dodds. I bet you can recognize who is who here, without me asking. So guys thank you so much for being here today, and we're excited to get the updates from you. As you might imagine, at this conference so far this week, we've always -- we've been starting the conversations with the macro stuff.
Questions and Answers:
Amit Hazan - Goldman Sachs Group, Inc., Research Division - Equity AnalystThat's still top of mind
Trustpilot
